Literature DB >> 9213499

[Conservative therapy in renal carcinoma: follow-up].

C Buizza1, D Antonelli, S Chisena, S Bernasconi, A Zaroli, M Belloni, A Mandressi.   

Abstract

Due to the increasing use of sophisticated imaging techniques, up to 30% of diagnosed renal cell carcinoma (RCC) are asymptomatic and diagnosed incidentally. Getting the cue from our personal survey of conservative renal surgery for renal cell carcinoma with a cancer specific survival of 95.5% after a mean follow up of 32.7 months, a review of the literature is illustrated: numerous studies have documented the technical success rate with this approach as well as long term disease free survival, comparable to that obtained by radical nephrectomy, in patients with unilateral, small, low stage tumors and normal opposite kidney. Patient selection is of extreme importance in case of partial resection in the presence of a normal contralateral kidney. The tumor must be < 3-4 cm, solitary, well delineated on CT, without invasion of the perinephric far or pyelocaliceal system (T1 and T2), easily resectable with at least 1 cm of healthy parenchyma. Only well informed patients who agree on a careful follow up after surgery can be candidates for kidney sparing surgery. In case of imperative surgery the follow up must be strict and personified for every single patient. Those patients who underwent a partial nephrectomy in presence of a normal contralateral kidney should be monitored with a conventional follow up monitored in order to detect an eventual local recurrence: 12 monthly ultrasonography and contrast enhanced CT scan alternately every 6 months for the first five years after surgery and then lifelong once a year by echography and/or CT scan.

Entities:  

Mesh:

Year:  1997        PMID: 9213499

Source DB:  PubMed          Journal:  Arch Ital Urol Androl        ISSN: 1124-3562


  1 in total

1.  Double partial nephrectomy in a patient with two adenocarcinomas in a solitary kidney.

Authors:  A Giannopoulos; G Kyriakou; C Constantinides; T Manousakas; A Kyroudi; C Dimopoulos
Journal:  Int Urol Nephrol       Date:  2000       Impact factor: 2.370

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.